Founded in 2016, JY BioMed (Ji Yan Biomedical) transitioned from health supplements to biotechnology and pharmaceutical research in 2020, expanding its expertise and market potential. The company specializes in personalized medicine, using dendritic cells (DCs) and MSC-derived exosomes to enhance immune responses against cancer. Their therapies, including DC cancer vaccines and Gamma-Delta T cell treatments, offer precise, broad-spectrum anti-tumor activity. Additionally, MSC-based products support regenerative medicine, promoting tissue repair and immune modulation. With a strong R&D focus, JY BioMed develops innovative therapies for cancer, ocular diseases, and skin regeneration, pushing medical frontiers to improve patient care.

JY BioMed

Org chart

Teams

Offices

JY BioMed

Org chart

Teams

Offices

Related companies